NAD+ Precursors (NMN)
Overview
Nicotinamide mononucleotide (NMN) is a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular metabolism, DNA repair (via sirtuins and PARPs), and circadian rhythm regulation. NAD+ levels decline with age, and NMN supplementation restores tissue NAD+ levels, activating SIRT1-mediated pathways that regulate mitochondrial biogenesis and oxidative stress resistance.
Key Research Findings
Long-term NMN administration improved age-related physiological decline in mice including insulin sensitivity, lipid profiles, and physical activity (Mills et al., Cell Metabolism, 2016). Human clinical trial showed increased NAD+ metabolites and improved muscle insulin sensitivity in prediabetic women (Yoshino et al., Science, 2021). Multiple Phase 2 trials ongoing.
Oral, Intravenous, Sublingual
In Clinical Trials
Interested in NAD+ Precursors (NMN)?
Find a verified provider experienced with NAD+ Precursors (NMN) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a NAD+ Precursors (NMN) ProviderRelated Peptides
Epithalon (Epitalon)
Research PhaseA synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural epithalamin peptide produced by the pineal gland. Epithalon activates telomerase, the enzyme responsible for maintaining telomere length, thereby potentially extending cellular replicative capacity. It also stimulates melatonin production and modulates neuroendocrine system function associated with aging.
MOTS-c
Research PhaseA mitochondrial-derived peptide encoded by the 12S rRNA gene of mitochondrial DNA. MOTS-c is a 16-amino acid peptide that acts as an exercise mimetic by activating AMPK and regulating metabolic homeostasis. It translocates to the nucleus under metabolic stress to regulate nuclear gene expression related to glucose metabolism and cellular stress responses.
Humanin
Research PhaseA 24-amino acid mitochondrial-derived peptide encoded within the 16S rRNA region of mitochondrial DNA. Humanin exerts cytoprotective and neuroprotective effects by interacting with IGFBP-3, BAX, and the FPRL-1 receptor. It inhibits apoptosis through suppression of the intrinsic mitochondrial death pathway and reduces amyloid-beta-induced neurotoxicity.
SS-31 (Elamipretide)
In Clinical TrialsA mitochondria-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that selectively concentrates in the inner mitochondrial membrane by binding to cardiolipin. SS-31 stabilizes cytochrome c interactions with cardiolipin, optimizing electron transport chain efficiency and reducing mitochondrial reactive oxygen species (ROS) production. It restores mitochondrial bioenergetics in aged and diseased tissues without acting as a conventional antioxidant scavenger.